Medically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is ...

The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

为探究乳腺癌脑转移（BCBMs）治疗策略变化对患者结局的影响，意大利和法国多家机构研究人员开展相关研究。结果发现仅 HR-/HER2 + 患者总生存期改善。该研究对优化治疗、评估预后意义重大，值得科研读者一读。

点击蓝字关注我们【导读】这项III期试验旨在比较ARX788和拉帕替尼加卡培他滨治疗人表皮生长因子受体2（HER2）阳性晚期乳腺癌（ABC）患者的疗效。2025年2月17日，NovoCodex ...

The following is a summary of "HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials ...

为解决 ER+、HER2 阳性或阴性转移性乳腺癌中 FDG 和 FES-PET 成像效用不明的问题，华盛顿大学等研究人员开展相关研究，发现两者摄取相似，FES-PET 或可筛选患者。推荐阅读，了解乳腺癌诊疗新依据。

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...

Stephanie Seban has devoted the last 14 years of her life to being a 'north star' to other young women facing stage four ...

Philecia La'Bounty uses social media to encourage others to get screenings, be open about their experiences and share her own battles — and her followers have shown appreciation. Read more about her ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...